Titre : Précurseurs lymphoïdes T

Précurseurs lymphoïdes T : Questions médicales fréquentes

Termes MeSH sélectionnés :

Platelet Function Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Précurseurs lymphoïdes T : Questions médicales les plus fréquentes", "headline": "Précurseurs lymphoïdes T : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Précurseurs lymphoïdes T : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-22", "dateModified": "2025-04-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Précurseurs lymphoïdes T" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cellules souches", "url": "https://questionsmedicales.fr/mesh/D013234", "about": { "@type": "MedicalCondition", "name": "Cellules souches", "code": { "@type": "MedicalCode", "code": "D013234", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.872" } } }, "about": { "@type": "MedicalCondition", "name": "Précurseurs lymphoïdes T", "alternateName": "Precursor Cells, T-Lymphoid", "code": { "@type": "MedicalCode", "code": "D054504", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Robert Gniadecki", "url": "https://questionsmedicales.fr/author/Robert%20Gniadecki", "affiliation": { "@type": "Organization", "name": "Division of Dermatology, Department of Medicine, and." } }, { "@type": "Person", "name": "Aneta Pankow", "url": "https://questionsmedicales.fr/author/Aneta%20Pankow", "affiliation": { "@type": "Organization", "name": "Oklahoma Medical Research Foundation, Program in Arthritis and Clinical Immunology, 825 NE 13Street, Oklahoma City, OK 73104, USA." } }, { "@type": "Person", "name": "Xiao-Hong Sun", "url": "https://questionsmedicales.fr/author/Xiao-Hong%20Sun", "affiliation": { "@type": "Organization", "name": "Oklahoma Medical Research Foundation, Program in Arthritis and Clinical Immunology, 825 NE 13Street, Oklahoma City, OK 73104, USA." } }, { "@type": "Person", "name": "Fernando Gallardo", "url": "https://questionsmedicales.fr/author/Fernando%20Gallardo", "affiliation": { "@type": "Organization", "name": "Dermatology Department, Parc de Salut Mar-Hospital del Mar, Barcelona, Spain. Electronic address: fgallardo@parcdesalutmar.cat." } }, { "@type": "Person", "name": "Tom Taghon", "url": "https://questionsmedicales.fr/author/Tom%20Taghon", "affiliation": { "@type": "Organization", "name": "The Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent University Hospital, Ghent, Belgium. Tom.Taghon@ugent.be." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Flow Cytometry and Platelets.", "datePublished": "2024-06-04", "url": "https://questionsmedicales.fr/article/39089755", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cll.2024.04.011" } }, { "@type": "ScholarlyArticle", "name": "On-treatment platelet reactivity through the thromboxane A", "datePublished": "2023-06-20", "url": "https://questionsmedicales.fr/article/37338713", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11239-023-02818-6" } }, { "@type": "ScholarlyArticle", "name": "Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology.", "datePublished": "2023-06-16", "url": "https://questionsmedicales.fr/article/37331519", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jtha.2023.05.027" } }, { "@type": "ScholarlyArticle", "name": "Advances in Platelet-Dysfunction Diagnostic Technologies.", "datePublished": "2024-06-17", "url": "https://questionsmedicales.fr/article/38927117", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biom14060714" } }, { "@type": "ScholarlyArticle", "name": "Postinjury platelet aggregation and venous thromboembolism.", "datePublished": "2022-05-21", "url": "https://questionsmedicales.fr/article/35444156", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/TA.0000000000003655" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules souches", "item": "https://questionsmedicales.fr/mesh/D013234" }, { "@type": "ListItem", "position": 4, "name": "Précurseurs lymphoïdes T", "item": "https://questionsmedicales.fr/mesh/D054504" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Précurseurs lymphoïdes T - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Précurseurs lymphoïdes T", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Précurseurs lymphoïdes T", "description": "Comment diagnostiquer une anomalie des précurseurs lymphoïdes T ?\nQuels marqueurs sont utilisés pour identifier les précurseurs T ?\nQuels examens sont recommandés pour évaluer les précurseurs T ?\nLes tests génétiques sont-ils utiles pour les précurseurs T ?\nQuelle est l'importance de l'immunophénotypage ?", "url": "https://questionsmedicales.fr/mesh/D054504?mesh_terms=Platelet+Function+Tests&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Précurseurs lymphoïdes T", "description": "Quels symptômes indiquent un problème avec les précurseurs T ?\nLes symptômes varient-ils selon l'âge ?\nComment les troubles des précurseurs T affectent-ils l'immunité ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours visibles ?", "url": "https://questionsmedicales.fr/mesh/D054504?mesh_terms=Platelet+Function+Tests&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Précurseurs lymphoïdes T", "description": "Peut-on prévenir les troubles des précurseurs T ?\nL'éducation sur les infections est-elle importante ?\nLes vaccinations sont-elles recommandées ?\nComment le dépistage précoce aide-t-il ?\nY a-t-il des recommandations alimentaires ?", "url": "https://questionsmedicales.fr/mesh/D054504?mesh_terms=Platelet+Function+Tests&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Précurseurs lymphoïdes T", "description": "Quels traitements sont disponibles pour les troubles des précurseurs T ?\nLa thérapie génique est-elle une option ?\nLes immunothérapies sont-elles efficaces ?\nQuel rôle joue la surveillance médicale ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D054504?mesh_terms=Platelet+Function+Tests&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Précurseurs lymphoïdes T", "description": "Quelles complications peuvent survenir avec des troubles T ?\nLes troubles des précurseurs T peuvent-ils entraîner des cancers ?\nComment les infections opportunistes affectent-elles les patients ?\nLes troubles T peuvent-ils affecter d'autres organes ?\nY a-t-il des risques de rechute après traitement ?", "url": "https://questionsmedicales.fr/mesh/D054504?mesh_terms=Platelet+Function+Tests&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Précurseurs lymphoïdes T", "description": "Quels sont les facteurs de risque pour les troubles T ?\nL'âge influence-t-il le risque de troubles T ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'exposition à des toxines joue-t-elle un rôle ?\nLe mode de vie influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D054504?mesh_terms=Platelet+Function+Tests&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des précurseurs lymphoïdes T ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies de moelle osseuse sont utilisés pour le diagnostic." } }, { "@type": "Question", "name": "Quels marqueurs sont utilisés pour identifier les précurseurs T ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs CD34 et CD7 sont souvent utilisés pour identifier les précurseurs T." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour évaluer les précurseurs T ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une cytométrie en flux et une analyse génétique peuvent être recommandées." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les précurseurs T ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à identifier des anomalies génétiques spécifiques dans les précurseurs T." } }, { "@type": "Question", "name": "Quelle est l'importance de l'immunophénotypage ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'immunophénotypage permet de caractériser les types de cellules lymphoïdes T présentes." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec les précurseurs T ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, infections fréquentes et anomalies sanguines peuvent indiquer un problème." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de l'état immunitaire." } }, { "@type": "Question", "name": "Comment les troubles des précurseurs T affectent-ils l'immunité ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent entraîner une immunodéficience, rendant le corps vulnérable aux infections." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées ou des infections cutanées peuvent survenir en cas de troubles." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours visibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains troubles peuvent être asymptomatiques au début de leur développement." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles des précurseurs T ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures préventives, comme un mode de vie sain, peuvent aider à réduire les risques." } }, { "@type": "Question", "name": "L'éducation sur les infections est-elle importante ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur la prévention des infections est cruciale pour les patients à risque." } }, { "@type": "Question", "name": "Les vaccinations sont-elles recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccinations peuvent aider à protéger contre certaines infections opportunistes." } }, { "@type": "Question", "name": "Comment le dépistage précoce aide-t-il ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce permet d'identifier les problèmes avant qu'ils ne deviennent graves." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir le système immunitaire et la santé des précurseurs T." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les troubles des précurseurs T ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chimiothérapie, la radiothérapie et les greffes de moelle." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique est explorée pour corriger des anomalies dans les précurseurs T." } }, { "@type": "Question", "name": "Les immunothérapies sont-elles efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les immunothérapies peuvent aider à renforcer la réponse immunitaire des précurseurs T." } }, { "@type": "Question", "name": "Quel rôle joue la surveillance médicale ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance régulière est cruciale pour ajuster les traitements et surveiller l'évolution." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des troubles T ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections graves, des cancers et des troubles auto-immuns." } }, { "@type": "Question", "name": "Les troubles des précurseurs T peuvent-ils entraîner des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles peuvent augmenter le risque de développer des cancers hématologiques." } }, { "@type": "Question", "name": "Comment les infections opportunistes affectent-elles les patients ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent causer des maladies graves chez les patients immunodéprimés." } }, { "@type": "Question", "name": "Les troubles T peuvent-ils affecter d'autres organes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent entraîner des complications dans d'autres systèmes organiques." } }, { "@type": "Question", "name": "Y a-t-il des risques de rechute après traitement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des rechutes peuvent survenir, nécessitant une surveillance continue." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles T ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des infections virales et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de troubles T ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente souvent avec l'âge, en raison de l'affaiblissement du système immunitaire." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent augmenter le risque de troubles des précurseurs T." } }, { "@type": "Question", "name": "L'exposition à des toxines joue-t-elle un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut augmenter le risque de troubles lymphoïdes T." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut contribuer à un risque accru de troubles des précurseurs T." } } ] } ] }

Sources (10000 au total)

On-treatment platelet reactivity through the thromboxane A

Pelacarsen decreases plasma levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPL). It was previously reported that pelacarsen does not affect the platelet count. We now report the effect ... Subjects with established cardiovascular disease and screening Lp(a) levels ≥60 mg per deciliter (~ ≥150 nmol/L) were randomized to receive pelacarsen (20, 40, or 60 mg every 4 weeks; 20 mg every 2 we... Of the 286 subjects randomized, 275 had either an ARU or PRU test, 159 (57.8%) were on aspirin alone and 94 (34.2%) subjects were on dual anti-platelet therapy. As expected, the baseline ARU and PRU w... Pelacarsen does not modify on-treatment platelet reactivity through the thromboxane A...

Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology.

Light transmission aggregation (LTA) is used widely by the clinical and research communities. Although it is a gold standard, there is a lack of interlaboratory harmonization.... The primary objective was to assess whether sources of activators (mainly adenosine diphosphate [ADP], collagen, arachidonic acid, epinephrine, and thrombin receptor activating peptide6) and ristoceti... An international multicenter study involving 28 laboratories in which we compared LTA results obtained with center-specific activators and a comparator that we supplied.... We report variability in the potency (P) of activators in comparison with the comparator. Thrombin receptor activating peptide 6 (P, 1.32-2.68), arachidonic acid (P, 0.87-1.43), and epinephrine (P, 0.... Based on these data, the establishment and adoption of simple standardization principles should mitigate variability due to activator sources. The observation of huge interindividual variability for c...

Postinjury platelet aggregation and venous thromboembolism.

Posttraumatic venous thromboembolism (VTE) remains prevalent in severely injured patients despite chemoprophylaxis. Importantly, although platelets are central to thrombosis, they are not routinely ta... We performed a secondary analysis of 133 severely injured patients from a prospective observational study investigating coagulation and inflammation (2011-2019). Platelet aggregation in response to st... The 133 patients were severely injured (median Injury Severity Score, 25), and 14% developed VTE (all >48 hours after admission). At presentation, platelet count and PA were not significantly differen... Severely injured patients with decreasing ex vivo measures of PA despite resuscitation have an increased risk of developing VTE. This may have implications for predicting development of VTE and for st... Prognostic/Epidemiological; Level III....

Gamma and X-ray irradiation do not affect the in vitro quality of refrigerated apheresis platelets in platelet additive solution (PAS-E).

Platelet refrigeration (cold storage) provides the advantages of an extended shelf life and reduces the risk of bacterial growth, compared to platelets stored at room temperature (RT). However, proces... Triple-dose apheresis platelets were collected in 40% plasma/60% PAS-E, using the TRIMA apheresis platform, and refrigerated (2-6°C) within 8 h of collection. On day 2, one of each component was gamma... The platelet concentration decreased by approximately 20% in all groups during 21 days of storage (p > .05). Irradiation (gamma or X-ray) did not affect platelet metabolism, and the pH was maintained ... Gamma and X-ray irradiation do not affect the in vitro quality of platelet components stored in the cold for up to 21 days. This demonstrates the acceptability of irradiating cold-stored platelets, wh...

In vitro quality of cold and delayed cold-stored platelet concentrates from interim platelet units during storage for 21 days.

Based on previous success using apheresis platelets, we wanted to investigate the in vitro quality and platelet function in continuously cold-stored and delayed cold-stored platelet concentrates (PCs)... We used a pool-and-split design to prepare 18 identical pairs of PCs. One unit was stored unagitated and refrigerated after production on day 1 (cold-stored). The other unit was stored agitated at roo... All PCs complied with European recommendations (EDQM 20th edition). Both groups had mean platelet content >200 × 10... Our findings suggest that PCs from IPUs are suitable for cold storage from day 1 until day 21 and delayed cold storage from day 5 until day 14....

Hyperbaric treatment of platelets extends in vitro storage to 14 days.

Platelets for transfusion have a storage time of 5-7 days at 22°C-24°C, which results in a strain on the supply chain and supply shortages. We describe a novel method to extend platelet storage using ... Apheresis platelets (APU) prepared in 65% platelet additive solution (PAS) were stored under standard conditions (SC) at 20°C-24°C to Day 5. Paired APUs were prepared with Xe and stored to Day 14 at 2... XHC platelets were viable out to Day 14. The average pH of Day 14 platelets was 6.58, and 86% maintained some degree of swirl compared with 7.02 and 100% swirl for Day 5 SC platelets. The rate of glyc... Platelet storage with the Xe/hyperbaric/cold method is a feasible candidate for extension of storage to 14 days based on in vitro characteristics. In vivo recovery and survival studies are indicated. ...

Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y

ADP-induced platelet activation leads to cell surface expression of several proteins, including TF (tissue factor). The role of ADP receptors in platelet TF modulation is still unknown. We aimed to as... The effects of P2Y... In blood from healthy subjects, stimulated in vitro by ADP, the percentage of TF... Data show that TF expression is regulated by P2Y...